author-photo

Qiaoyang Lu

Astellas Pharma

5

Papers

9

Citations

Citation Trend

Filter By

Papers (4) Sort By

Journal Conference Others

Follow-up of patients with FLT3-mutated R/R AML in the phase 3 ADMIRAL trial.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib

2020 Blood
Show All
- Source
- Cite
- Save
Citations (3)
Long-term survivors and gilteritinib safety beyond one year in FLT3-mutated R/R AML: ADMIRAL trial follow-up.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Clinical Outcomes Following Treatment with Gilteritinib or Quizartinib in Patients with Relapsed/Refractory FLT3-ITD+ Acute Myeloid Leukemia

2020 Blood
Show All
- Source
- Cite
- Save
Citations (2)